National Health (Pharmaceutical Benefits) Regulations (Amendment) (Cth)

Statutory Rules

1977 No. 221

REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953*

WHEREAS it is provided by sub-section 101 (4) of the National Health Act 1953 that a drug or medicinal preparation that was not a pharmaceutical benefit under that Act immediately before the commencement of that sub-section shall not be prescribed as a pharmaceutical benefit in accordance with section 85 of that Act unless the Pharmaceutical Benefits Advisory Committee has recommended to the Minister that it be so prescribed:

AND WHEREAS that Committee has recommended to the Minister that the following drugs and medicinal preparations be prescribed as pharmaceutical benefits under section 85 of the National Health Act 1953, namely the drugs and medicinal preparations specified in Schedule 3to the National Health (Pharmaceutical Benefits) Regulations, as amended by the following Regulations, that had not previously been prescribed as pharmaceutical benefits:

NOW THEREFORE I, THE GOVERNOR-GENERAL of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953.

Dated this eighteenth day of November 1977.

John R. Kerr

Governor-General

By His Excellency’s Command,

SGD. RALPH J. HUNT

Minister of State for Health

___________

 

AMENDMENTS OF THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS 

Commencement

• 1.

  These Regulations shall come into operation on 1 December 1977.

____________________________________________________________________________________

* Notified in the Commonwealth of Australia Gazette on 24 November 1977.

  Statutory Rules 1900, No. 17 as amended to date. For previous amendments of the National Health (Pharmaceutical Benefits) Regulations see footnote   to Statutory Rules 1977, No. 39 and see also Statutory Rules 1977, Nos. 39 and 125.

16200/77 Cat. No. —Recommended retail price 20c  12/4.11.1977

Schedule 1

2.Schedule 1 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 1.

Schedule 2

3. Schedule 2 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 2.

Schedule 3

4. Schedule 3 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 3.

Schedule 5

5. Schedule 5 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 4.

____________

 

SCHEDULE 1 Regulation 2

AMENDMENTS OF SCHEDULE 1 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS

1. After item 203 insert the following item:

“ 203a Emetine and Bismuth Iodide Tablets ”.

• 2.

  After item 327 insert the following item:

“ 327a Lincomycin Hydrochloride ”.

• 3.

  After item 465 insert the following item:

“ 465a Phenolphthalein ”.

• 4.

  After item 555 insert the following item:

“ 555a Sodium Calciumedetate Injection ”.

• 5.

  After item 630 insert the following item:

“ 630a Trisodium Edetate Injection ”.

_______________

 

SCHEDULE 2 Regulation 3

AMENDMENTS OF SCHEDULE 2 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS.

1. After item 32 insert the following item:
“ 32a Betamethasone Valerate.......................................................	— ”.
2. After item 41 insert the following item:
“ 41a Cephalexin..............................................................................	Purified Water, B.P., with Cephalexin ”,
3. Omit item 120.
4. After item 133 insert the following item:
“ 133a Miconazole Nitrate..............................................................	— ”.
5. Omit item 163.
6. Omit item 187.
7. After item 218 insert the following item:
“ 218a Triglycerides Oil, Medium Chain	— ”.

_____________

 

SCHEDULE 3 Regulation 4

AMENDMENTS OF SCHEDULE 3 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS

1. After item 208 insert the following items:

“ 208a Metoprolol Tartrate

“ 208b Miconazole Nitrate ”.

2. After item 277 insert the following item:

“ 277a Rabies Immune Globulin, Human ”.

3. Omit item 295.

4. After item 343 insert the following item:

“ 343a Triglycerides Oil, Medium Chain ”.

SCHEDULE 4  Regulation 5

AMENDMENTS OF SCHEDULE 5 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS

1. Omit item 4, substitute the following items:
“ 4 Alginic Acid Compound Powder	With the written authority of the Director-General, cardio-oesophageal reflux
“ 4a Alginic Acid Compound Granules	With the written authority of the Director-General, cardio oesophageal reflux not responding to antacid therapy ”.
2. Omit item 19, substitute the following item:
“ 19 (1) Calciferol, B.P.	With the written authority of the Director-General—
(2) Calciferol Tablets, Strong, B.P.
	Hypocalcaemia
Hypoparathyroidism
Osteomalacia following gastrectomy, severe steatorrhoea or renal failure
Vitamin D-resistant rickets ”.
3. Omit item 23, substitute the following item:
“ 23 Carbenicillin Sodium	Any disease or condition in a patient receiving treatment in or at an approved hospital
With the written authority of the Director-General—
Infections where positive bacteriological evidence confirms that carbenicillin is the most appropriate therapeutic agent
Septicaemia, suspected or proven ”
4. Omit item 26, substitute the following item:
“ 26 Cephaloridine	Endophthalmitis
Infections where positive bacteriological evidence conforms that cephaloridine is the most appropriate therapeutic agent ”.
5. Omit item 39, substitute the following item:
“ 39 (1) Clindamycin Hydrochloride	Gram-positive coccal infections where the infection cannot be safely and effectively treated with penicillin or a derivative of penicillin ”.
(2) Clindamycin Palmilate Hydrochloride
6. Omit item 47, substitute the following item:
“ 47 (1) Cyclophosphamide, B.P.	Any disease or condition in a patient receiving treatment in or at an approved hospital
(2) Cyclophosphamide Tablets, B.P.
With the written authority of the Director-General—
Anaemia, autoimmune, haemolytic
Arthritis, rheumatoid with vasculitis or visceral complications
Continuing cyclophosphamide therapy after discharge from an approved hospital
Crohn’s disease
Dermatomyositis
Granulomatosis, Wegener’s
Hepatitis, active, chronic
Lupus erythematosus, systemic
Malignant disease, including leukaemia
Nephritis
Nephrotic syndrome
Pemphigus vulgaris
Polyarteritis nodosa
Scleroderma
Thrombocytopenic purpura
Ulcerative colitis ”.
7. Omit item 63, substitute the following item:
“ 63 Fluoxymesterone Tablets, B.P.	With the written authority of the Director-General—
Aplastic anemias, proven
Carcinoma of the beast
Hypogonadism
Osteoporosis ”.

 

8. Omit item 70, substitute the following item:
“ 70 Gentamicin Injection, B.P.	Any disease or condition in a patient receiving treatment in or at an approved hospital
Endophthalmitis
With the written authority of the Director-General—
Infections where positive bacteriological evidence confirms that gentamicin sulphate is the most appropriate antibiotic
Septicaemia including suspected septicaemia ”.
9. Omit item 76, substitute the following item:
“ 76 (1) Haloperidol	Any disease or condition in a patient receiving treatment in or at an approved hospital
(2) Haloperidol Tablets, B.P., 1.5 mg
Chorea
Hyperactive states of organic or toxic delirium
Malignant neoplasia (late stage)
Radiation sickness
Major psychoses including—
Major organic psychoses including arteriopathic dementia
Manic-depressive psychosis
Paranoid states
Schizophrenia
Senile dementia ”.
10. After item 76 insert the following item:
“ 76a Haloperidol Tablets, B.P., 5 mg	For use in a hospital for acute schizophrenia or mania ”.
11. Omit item 88, substitute the following item:
“ 88 (1) Levodopa, B.P., with Carbidopa	Treatment of Parkinson’s Disease ”.
(2) Levodopa Capsules, B.P.
(3) Levodopa Tablets, B.P.
12. Omit item 89.
13. Omit item 90.
14. Omit item 91.
15. Omit item 104, substitute the following item:
“ 104 Methicillin Sodium, B.P., for injection	Endophthalmitis
	Proven or suspected staphylococcal septicaemia ”.
16. Omit item 107, substitute the following item:
“ 107 Methylprednisolone Acetate Injection	For local intra-articular or peri-articular infiltration ”.
17. Omit item 110, substitute the following item:
“ 110 (1) Methylteslosterone, B.P.	Carcinoma of the breast
(2) Methyltestosterone Tablets, B.P., 25 mg or 50 mg	Hypogonadism
	Klinefelter’s syndrome (seminiferous tubule dysgenesis) ”.
18. After item 111 insert the following items:
“ 111a Metoprolol Tartrate	With the written authority of the Director-General, frequent disabling angina without evidence of cardiac failure
“ 111b Miconazole Nitrate	Cutaneous candidiasis
Dermatomycosis
Pityriasis versicolor ”.
19. Omit item 115, substitute the following item:
“ 115 Nandrolone Decanoate Injection, B.P.	With the written authority of the Director-General—
Carcinoma of the breast
Osteoporosis
Patients on long-term treatment with corticosteroids ”.

 

20.	Omit item 116, substitute the following item:
“ 116 Nandrolone Phenylpropionate Injection, B.P.	With the written authority of the Director-General—
Carcinoma of the breast
Osteoporosis
Patients on long-term treatment with corticosteroids ”.
21.	Omit item 129.
22.	Omit item 132, substitute the following item:
“ 132 Phenelzine Tablets, B.P.	Depressive illness resistant to treatment with tricyclic antidepressants or electroconvulsive therapy
Phobic states ”.
23.	Omit item 152.
24.	Omit item 155, substitute the following item:
“ 155 Sodium Nitroprusside	For use in a hospital ”.
25.	Omit item 158, substitute the following item:
“ 158 Stanolone Tablets, B.P.	With the written authority of the Director-General—
Carcinoma of the breast
Osteoporosis
Patients on long-term treatment with corticosteroids ”.
26.	Omit item 167, substitute the following item:
“ 167 Thiamine Hydrochloride Tablets, B.P.	Any disease or condition in a pensioner ”.
27.	Omit item 172, substitute the following item:
“ 172 Tranylcypromine Tablets, B.P.	Depressive illness resistant to treatment with tricyclic anti-depressants or electroconvulsive therapy
Phobic states ”.
28.	After item 174 insert the following item:
“ 174a Triglycerides Oil, Medium Chain	With the written authority of the Director-General, patients requiring a ketogenic diet for intractable childhood epilepsy ”.
29.	Omit item 175, substitute the following item:
“ 175 ‘ TRIGLYDE ’	With the written authority of the Director-General—
Patients requiring a ketogenic diet for intractable childhood epilepsy
Proven malabsorption ”.
30.	Omit item 177, substitute the following item:
“ 177 Vancomycin Hydrochloride	Any disease or condition in a patient receiving treatment in a hospital
Endophthalmitis ”;

                    

Printed by Authority by the Acting Commonwealth Government Printer